We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Approval Drop. In this article, we ...

The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and projected demand in the country, the Danish pharmaceutical company said.

The resolution could potentially restrict how telehealth programs offer cheaper versions known as compounded drugs ...

Demand GLP-1 Medications as Prescription Drug Market GrowsSchaumburg, Illinois, Feb 21, 2025 - (ACN Newswire) - Giftify, Inc.

The FDA determined that Novo Nordisk’s obesity and diabetes drugs were no longer in short supply. Elsewhere, Concentra made a ...

The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can ...

Novo Nordisk ( NVO 5.29%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly ...

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

The U.S. FDA declared that Novo Nordisk's weight loss and diabetes drugs, Ozempic and Wegovy, are no longer in shortage.

The massive crash came after the US Food and Drug Administration (FDA) website showed the end of the shortage of Novo Nordisk ...

The U.S. drug regulator declared that the shortage of weight-loss medications Wegovy and Ozempic has been resolved, Danish pharma giant Novo Nordisk said.

The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.